*People with moderate to severe liver impairment *Concurrent use of moderate to strong inducers of CYP3A and strong inducers of CYP2C8 reduce efficacy
Ombitasvir/paritaprevir/ritonavir
Atazanavir/ritonavir
Atazanavir/cobicistat
Sofosbuvir/velpatasvir/voxilaprevir
Glecaprevir/pibrentasvir
Abacavir/lamivudine
Sofosbuvir/velpatasvir
Abacavir/lamivudine/zidovudine